Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer
2015 (English)In: Clinical Proteomics, ISSN 1542-6416, E-ISSN 1559-0275, Vol. 12, no 1, 8- p.Article in journal (Refereed) Published
BACKGROUND: Despite the success of tamoxifen since its introduction, about one-third of patients with estrogen (ER) and/or progesterone receptor (PgR) - positive breast cancer (BC) do not benefit from therapy. Here, we aim to identify molecular mechanisms and protein biomarkers involved in tamoxifen resistance.
RESULTS: Using iTRAQ and Immobilized pH gradient-isoelectric focusing (IPG-IEF) mass spectrometry based proteomics we compared tumors from 12 patients with early relapses (<2 years) and 12 responsive to therapy (relapse-free > 7 years). A panel of 13 proteins (TCEAL4, AZGP1, S100A10, ALDH6A1, AHNAK, FBP1, S100A4, HSP90AB1, PDXK, GFPT1, RAB21, MX1, CAPS) from the 3101 identified proteins, potentially separate relapse from non-relapse BC patients. The proteins in the panel are involved in processes such as calcium (Ca(2+)) signaling, metabolism, epithelial mesenchymal transition (EMT), metastasis and invasion. Validation of the highest expressed proteins in the relapse group identify high tumor levels of CAPS as predictive of tamoxifen response in a patient cohort receiving tamoxifen as only adjuvant therapy.
CONCLUSIONS: This data implicate CAPS in tamoxifen resistance and as a potential predictive marker.
Place, publisher, year, edition, pages
2015. Vol. 12, no 1, 8- p.
CAPS; Calcyphosine; Endocrine resistance; Estrogen receptor; MX1; Proteomics; Receptor-positive breast cancer
Cancer and Oncology Cell and Molecular Biology
IdentifiersURN: urn:nbn:se:liu:diva-125931DOI: 10.1186/s12014-015-9080-yPubMedID: 25878567OAI: oai:DiVA.org:liu-125931DiVA: diva2:910424